Dashboard
Manage Tickers

RAPT RAPT Therapeutics, Inc.

Nasdaq rapt.com


$ 28.83 $ 0.77 (2.72 %)    

Thursday, 06-Nov-2025 15:59:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 613.47 $ 0.00 (0 %)
DIA $ 470.14 $ 0.00 (0 %)
SPY $ 672.05 $ 0.00 (0 %)
TLT $ 89.46 $ 0.00 (0 %)
GLD $ 368.86 $ 0.00 (0 %)
$ 29.04
$ 28.27
$ 15.00 x 1
$ 35.75 x 20
-- - --
$ 5.67 - $ 42.39
308,205
na
804.72M
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-07-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-11-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-10-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-16-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-30-2020 12-31-2019 10-K
25 12-11-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rapt-therapeutics-q3-eps-065-beats-080-estimate
RAPT Therapeutics Q3 EPS $(0.65) Beats $(0...
11/06/2025 13:30:19

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0...

wells-fargo-maintains-overweight-on-rapt-therapeutics-raises-price-target-to-72
Wells Fargo Maintains Overweight on RAPT T...
11/03/2025 14:11:17

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $...

hc-wainwright--co-maintains-buy-on-rapt-therapeutics-raises-price-target-to-72
HC Wainwright & Co. Maintains Buy on RAPT ...
10/27/2025 16:57:39

HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price targe...

guggenheim-initiates-coverage-on-rapt-therapeutics-with-buy-rating-announces-price-target-of-70
Guggenheim Initiates Coverage On RAPT Ther...
10/27/2025 12:11:40

Guggenheim analyst Yatin Suneja initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price ...

rapt-therapeutics-initiates-prestige-phase-2b-clinical-trial-of-ozureprubart-rpt904-in-patients-with-food-allergies
RAPT Therapeutics Initiates prestIgE Phase...
10/27/2025 12:07:40

reported-earlier-rapt-therapeutics-prices-8333334-common-shares-at-30-each-in-250m-offering-to-fund-expansion-of-novel-immunology-based-therapy-development-and-clinical-stage-programs
Reported Earlier, RAPT Therapeutics Prices...
10/22/2025 07:27:34

rapt-therapeutics-announces-common-stock-offering-terms-not-disclosed
RAPT Therapeutics Announces Common Stock O...
10/21/2025 20:02:32

RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on ...

wells-fargo-maintains-overweight-on-rapt-therapeutics-raises-price-target-to-48
Wells Fargo Maintains Overweight on RAPT T...
10/21/2025 13:08:18

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $...

barclays-maintains-overweight-on-rapt-therapeutics-raises-price-target-to-58
Barclays Maintains Overweight on RAPT Ther...
10/21/2025 12:47:15

Barclays analyst Etzer Darout maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $...

clear-street-maintains-buy-on-rapt-therapeutics-raises-price-target-to-60
Clear Street Maintains Buy on RAPT Therape...
10/21/2025 11:35:21

Clear Street analyst Kaveri Pohlman maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $4...

jp-morgan-upgrades-rapt-therapeutics-to-overweight-raises-price-target-to-55
JP Morgan Upgrades RAPT Therapeutics to Ov...
10/20/2025 21:58:58

JP Morgan analyst Anupam Rama upgrades RAPT Therapeutics (NASDAQ:RAPT) from Neutral to Overweight and raises the price targe...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
10/20/2025 18:39:30

trading-halt-halt-status-updated-at-82500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:25:...
10/20/2025 12:25:08

rapt-therapeutics-and-shanghai-jeyou-announce-topline-data-from-jeyous-phase-2-trial-of-rpt904-as-monotherapy-in-chronic-spontaneous-urticaria
RAPT Therapeutics And Shanghai Jeyou Annou...
10/20/2025 12:07:41

-  RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing-  Efficacy sustained at...

trading-halt-halted-at-75500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:55:00 a.m. ET - ...
10/20/2025 11:55:04

why-delcath-systems-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket
Why Delcath Systems Shares Are Trading Hig...
10/20/2025 09:10:06

reported-sunday-rapt-therapeutics-to-release-phase-2-rpt904-data-addressing-immune-modulation-in-chronic-spontaneous-urticaria-during-october-20-webcast
Reported Sunday, RAPT Therapeutics To Rele...
10/20/2025 07:33:49

barclays-initiates-coverage-on-rapt-therapeutics-with-overweight-rating-announces-price-target-of-35
Barclays Initiates Coverage On RAPT Therap...
10/13/2025 12:12:27

Barclays analyst Etzer Darout initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces P...

clear-street-maintains-buy-on-rapt-therapeutics-raises-price-target-to-41
Clear Street Maintains Buy on RAPT Therape...
09/30/2025 12:27:23

Clear Street analyst Kaveri Pohlman maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $2...

rapt-wins-fda-approval-to-test-food-allergy-drug-in-mid-stage-study
RAPT Wins FDA Approval To Test Food Allerg...
09/29/2025 09:01:42

RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, dev...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION